COVID-19 vaccination and rare side effects
Guidance relating to blood clotting, myocarditis and Guillain-Barré Syndrome (GBS) after COVID-19 vaccination.
Information and guidance for health professionals on very rare conditions reported after COVID-19 vaccination.
Blood clotting
If you have any clinical concerns, patients should be urgently referred to hospital and to appropriate specialist services for further assessment, particularly if the symptoms are unexplained and present in combination with thrombocytopaenia.
The recommended management of this rare presenting condition is available from the British Society of Haematologists (BSH) with specific guidance produced by the Royal College of Emergency Medicine (RCEM), Emergency Departments and Acute Medical Units.
A brief guidance document on the primary care management of suspected thromboembolism with thrombocytopenia after COVID-19 vaccination has been produced by the Royal College of General Practitioners (RCGP).
Myocarditis and Guillain-Barré Syndrome (GBS)
If you have any clinical concerns, patients should be urgently referred to appropriate specialist services for further assessment. Further information and guidance will be added as it becomes available.
Guidance, training and resources relating to the COVID-19 vaccination programme are available.
Guidance on blood clotting
Leaflets on blood clotting
Guidance on myocarditis and pericarditis
Guidance on Guillain-Barré Syndrome
Updates to this page
Last updated 14 December 2021 + show all updates
-
Added 'COVID-19 vaccination observation period'.
-
Added myocarditis and pericarditis after COVID-19 vaccination guidance.
-
First published.